Therapeutic Drug Monitoring of Phenytoin. Rationale and Current Status

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 1990 Nov 1

PMID 2268985

Citations 13

Authors

M Levine

T Chang

Affiliations

Soon will be listed here.

Citing Articles

Estimation of Free Phenytoin Concentration in Critically Ill Patients with Hypoalbuminemia: Direct-measurement vs Traditional Equations.

Wilfred P, Mathew S, Chacko B, Prabha R, Mathew B Indian J Crit Care Med. 2022; 26(6):682-687.

PMID: 35836626 PMC: 9237157. DOI: 10.5005/jp-journals-10071-24235.

Management of Epileptic Seizures in Disorders of Consciousness: An International Survey.

Briand M, Lejeune N, Zasler N, Formisano R, Bodart O, Estraneo A Front Neurol. 2022; 12:799579.

PMID: 35087474 PMC: 8788407. DOI: 10.3389/fneur.2021.799579.

Electromembrane extraction as a new approach for determination of free concentration of phenytoin in plasma using capillary electrophoresis.

Seyfinejad B, Khoubnasabjafari M, Ziaei S, Ozkan S, Jouyban A Daru. 2020; 28(2):615-624.

PMID: 32803689 PMC: 7704831. DOI: 10.1007/s40199-020-00366-5.

Diphenytoin, riluzole and lidocaine: three sodium channel blockers, with different mechanisms of action, decrease hippocampal epileptiform activity.

Diao L, Hellier J, Uskert-Newsom J, Williams P, Staley K, Yee A Neuropharmacology. 2013; 73:48-55.

PMID: 23707481 PMC: 3766392. DOI: 10.1016/j.neuropharm.2013.04.057.

Selected pharmacokinetic issues of the use of antiepileptic drugs and parenteral nutrition in critically ill patients.

R M Salih M, Bahari M, Y Abd A Nutr J. 2011; 9:71.

PMID: 21194458 PMC: 3022641. DOI: 10.1186/1475-2891-9-71.

References

Taylor J, Murphy M, Berg M, Perry P, Lyon L, Ludden T . Phenytoin dosage requirements and pharmacokinetic variables. Clin Pharm. 1983; 2(3):253-7. View

Froscher W, Eichelbaum M, Gugler R, Hildenbrand G, PENIN H . A prospective randomised trial on the effect of monitoring plasma anticonvulsant levels in epilepsy. J Neurol. 1981; 224(3):193-201. DOI: 10.1007/BF00313281. View

Reynolds E, Chadwick D, Galbraith A . One drug (phenytoin) in the treatment of epilepsy. Lancet. 1976; 1(7966):923-6. DOI: 10.1016/s0140-6736(76)92709-4. View

Beck D, Farringer J, Ravis W, Robinson C . Accuracy of three methods for predicting concentrations of free phenytoin. Clin Pharm. 1987; 6(11):888-94. View

Privitera M, Homan R, Ludden T, Peck C, Vasko M . Clinical utility of a Bayesian dosing program for phenytoin. Ther Drug Monit. 1989; 11(3):285-94. DOI: 10.1097/00007691-198905000-00011. View

Vozeh S, Koelz A, Martin E, Magun H, SCOLLO-LAVIZZARI G, Follath F . Predictability of phenytoin serum levels by nomograms and clinicians. Eur Neurol. 1980; 19(6):345-52. DOI: 10.1159/000115174. View

Knott C, Reynolds F . Phenytoin-valproate interaction: importance of saliva monitoring in epilepsy. Br Med J (Clin Res Ed). 1982; 284(6308):13-6. PMC: 1495384. DOI: 10.1136/bmj.284.6308.13. View

Bouma P, Peters A, Arts R, Stijnen T, Van Rossum J . Discontinuation of antiepileptic therapy: a prospective study in children. J Neurol Neurosurg Psychiatry. 1987; 50(12):1579-83. PMC: 1032597. DOI: 10.1136/jnnp.50.12.1579. View

Neuvonen P . Bioavailability of phenytoin: clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 1979; 4(2):91-103. DOI: 10.2165/00003088-197904020-00002. View

10.

Johnson G, Kilpatrick C, Bury R, Fullinfaw R, Moulds R . Unbound phenytoin plasma concentrations in patients comedicated with sodium valproate--the predictive value of plasma albumin concentration. Br J Clin Pharmacol. 1989; 27(6):843-9. PMC: 1379813. DOI: 10.1111/j.1365-2125.1989.tb03448.x. View

11.

Vozeh S, Follath F . Nomographic estimation of time to reach steady-state serum concentration during phenytoin therapy. Eur J Clin Pharmacol. 1980; 17(1):33-5. DOI: 10.1007/BF00561674. View

12.

Allen J, Ludden T, Burrow S, Clementi W, Stavchansky S . Phenytoin cumulation kinetics. Clin Pharmacol Ther. 1979; 26(4):445-8. DOI: 10.1002/cpt1979264445. View

13.

Chiba K, Ishizaki T, Miura H, Minagawa K . Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient. J Pediatr. 1980; 96(3 Pt 1):479-84. DOI: 10.1016/s0022-3476(80)80705-0. View

14.

BUCHTHAL F, SVENSMARK O, SCHILLER P . Clinical and electroencephalographic correlations with serum levels of diphenylhydanotin. Arch Neurol. 1960; 2:624-30. DOI: 10.1001/archneur.1960.03840120030004. View

15.

Lund L, Berlin A, Lunde K . Plasma protein binding of diphenylhydantoin in patients with epilepsy. Agreement between the unbound fraction in plasma and the concentration in the cerebrospinal fluid. Clin Pharmacol Ther. 1972; 13(2):196-200. DOI: 10.1002/cpt1972132196. View

16.

. Diphenylhydantoin side effects and serum albumin levels. Clin Pharmacol Ther. 1973; 14(4):529-32. DOI: 10.1002/cpt1973144part1529. View

17.

Cobos J . High-dose phenytoin in the treatment of refractory epilepsy. Epilepsia. 1987; 28(2):111-4. DOI: 10.1111/j.1528-1157.1987.tb03635.x. View

18.

Vozeh S, Uematsu T, Aarons L, Maitre P, Landolt H, Gratzl O . Intravenous phenytoin loading in patients after neurosurgery and in status epilepticus. A population pharmacokinetic study. Clin Pharmacokinet. 1988; 14(2):122-8. DOI: 10.2165/00003088-198814020-00004. View

19.

Callaghan N, Garrett A, Goggin T . Withdrawal of anticonvulsant drugs in patients free of seizures for two years. A prospective study. N Engl J Med. 1988; 318(15):942-6. DOI: 10.1056/NEJM198804143181502. View

20.

Ludden T, Allen J, Schneider L, Stavchansky S . Rate of phenytoin accumulation in man: a simulation study. J Pharmacokinet Biopharm. 1978; 6(5):399-415. DOI: 10.1007/BF01062722. View